Introduction
Severe sepsis, or infection with systemic inflammation complicated by organ dysfunction, poses a substantial burden on healthcare systems around the world; projected to account for more than five million deaths globally each year 1 . Bloodstream infection (BSI) with the presence of bacteria and/or fungi in blood cultures, can quickly progress to septic shock, multi-organ failure and death, if not recognised and treated aggressively 1 . For example, mortality rates from septic shock have been estimated to be as high as ~50% 1 . Severe sepsis and septic shock leads to endothelial and epithelial damage and activation of several host inflammatory pathways (imbalances between pro-inflammatory factors and anti-inflammatory substances-inflammasome, autophagy, pyroptosis, apoptosis, neutrophil extracellular traps [NETs] , and microparticles, including extracellular microvesicles) [1] [2] [3] ; dysregulation of the complement system, coagulation cascade and fibrinolytic systems (microthrombi including 'immunothrombosis'); vasoregulatory dysfunction with relative resistance to vasopressors; ultimately with global tissue hypoxia from dysfunction of coagulation, vascular permeability and vascular tone 1 . Prolonged oxygen deprivation with shock leads to sequential cell death, endorgan damage, multi-system organ failure, and death. However, with advances in intensive care management and goal-directed interventions, early sepsis mortality has fallen, only to increase later after 'recovery' from acute events, prompting investigation of sepsis-induced alterations in immune function 4 . Sepsis is recognised to alter innate and adaptive immune responses for prolonged periods after clinical recovery, with immunosuppression being a consistent exemplar of such changes 4 . Consequently superinfection with various pathogens, including cytomegalovirus (CMV) and multiple other herpes group viruses, has become more commonly recognised 1, 4 .
Cytomegalovirus in the intensive care setting
Bidirectional interactions between CMV (both direct and indirect) and the host complicates our understanding of the impact of the virus and our ability to demonstrate direct causality 5 . Risk factors for CMV reactivation other than seropositivity are not fully defined in the ICU, although the degree of inflammation and number of blood transfusions are identified as risk factors in critically ill patients 6 . Further, there are variations in virulence of the virus due to different strains and mutations, deletions and rearrangements in viral genes that can influence how the virus replicates in the host 7 . These differences in pathogenicity can include indirect effects such as potentiating immunosuppression, and direct tissue damage from CMV replication with secondary inflammation [7] [8] [9] . The virus induces potent proinflammatory chemokines and cytokines that further modify host responses. Host genetic polymorphisms may contribute to some of the differences in clinical outcomes noted 7 . CMV also has a range of evasion strategies that impair both innate and adaptive elements of the host defence, including intrinsic cellular defences, NK (natural killer) cells and T cell-mediated immunity 8 . Further host innate and adaptive T cell responses are important in controlling CMV infection 5, 7 , as illustrated by CMV disease progression in AIDS patients and transplant patients with impaired T cell function. CMV reactivation in the intensive care unit (ICU) setting has been associated with important adverse clinical outcomes, including increased duration of mechanical ventilation, longer length of stay, and higher all-cause mortality 9 . There are a number of putative mechanisms that link CMV reactivation with adverse patient outcomes, but clinical data in the ICU setting is limited 1 . CMV reactivation may cause direct lung injury (CMV pneumonia), amplification of inflammation systemically and locally within the lung, or predisposition to other nosocomial infections 8 .
Cytomegalovirus reactivation in critically ill intensive care patients
Despite broad variability in study populations, methodologies for CMV detection, and analytical methods used, multiple studies have documented frequent CMV reactivation in non-immunocompromised adults in ICU with critical illness due to different causes. Higher rates of CMV infection in studies of seropositive patients suggest that reactivation of latent infection rather than primary infection is the principal category of viraemia in this setting. Against this backdrop, in this issue of Anaesthesia and Intensive Care a thought-provoking prospective cohort study is reported by Dr Ryosuke Osawa and colleagues from the VA Pittsburgh Medical Center in Pittsburgh 10 . Osawa et al describe the outcome for 100 CMV seropositive critically ill ICU patients with BSI causing severe sepsis 10 , showing that those patients with CMV reactivation had significantly fewer ICU-free and ventilator-free days 10 . On univariate analysis CMV viraemia was associated with patient age and the total number of blood transfusions received. Furthermore, in a multivariate analysis the authors found that compared to those patients with sepsis and BSI 'early' after ICU admission, the subset of patients who developed sepsis with BSI following at least 48 hours in the ICU had an increased risk of CMV viraemia and in this subgroup CMV reactivation negatively impacted on the patients' outcomes 10 . Several strengths of this study are worthy of special mention. The authors report a relatively large prospective cohort study, with polymerase chain reaction (PCR) assays used to quantitatively measure weekly whole blood CMV DNA viral loads (VL), use of standardised definitions of sepsis, standardised definitions of BSI, and a sound definition of the immunosuppressed versus immunocompetent host was used to exclude patients with known or overt immunosuppression. Further, thoughtful primary and secondary endpoints, together with insightful stratification of patients based upon duration of ICU stay (>48 hours versus <48 hours) before BSI onset, and alongside these key points several other patient-specific subgroups were studied. Nonetheless, in retrospect, some features of the design and the interpretation of this study's results 10 deserve consideration. To start, why did this study take six-and-a-half years to complete recruitment? Did this introduce any biases? Were cases requiring readmission to the ICU censored after the first or final ICU admission? These points seem ill-defined. Secondly, the authors also used an 'in-house' CMV PCR assay and reported the VL in copies/ml 10 , instead of the internationally agreed units of IU/ml 11 . Also, whilst the authors report CMV VL kinetic data, this data is rather limited; in addition the choice of cut-off for high-level CMV VL of >500 copies/ml 10 seems fairly low. There is no right or wrong definition of high-level CMV viraemia in this context, but other studies have used a threshold of >1,000 copies/ml 12 , and this does hamper direct comparison and integration of these results. Thirdly, why were other herpes group viruses also not studied? For example, aside from CMV, many other studies show that HHV-6 (and other herpes group virus) infections are also associated with adverse outcomes in a proportion of critically ill ICU patients 6 . Fourthly, are there potential issues with generalisability? For instance, there are potential inherent differences and limitations with a BSI sepsis cohort compared to a study that includes all patients with severe sepsis syndrome. Conversely, previous studies show that BSI per se does not contribute much to worsened ICU patient outcomes, assuming comparable severity of sepsis/critical illness at baseline 1 . Fifthly, what about lead-time biases? Baseline CMV VL were measured after a median of six days delay, implying some degree of lead-time bias. Further, prolonged ICU BSI patients are likely to incur some time-emergent biases in contrast to new ICU BSI cases. Lastly, despite the careful study design that utilised sophisticated analytical methods, unaccounted residual confounding is inherent to observational studies compared with randomised controlled studies. Indeed, this study was probably underpowered statistically to unequivocally refute the null hypothesis for some key outcome measures, including the primary endpoint. Hence, it seems likely that there is a risk of type II error for several study outcomes. Despite these relative limitations, the study by Osawa et al 10 has many overall strengths, accordingly providing further clarity to our emerging understanding of the significance of CMV reactivation in critically ill ICU patients.
Future studies and potential solutions
Whilst careful study designs and sophisticated analysis methods can help to reduce residual biases, they can never eliminate residual confounding arising from incomplete knowledge and measurement of established determinants of outcomes. Conversely, no randomised controlled studies have been conducted in critically ill ICU patients with CMV reactivation. Organisational difficulties with planning a phase III clinical study are wide-ranging. In essence, the logistical considerations of a randomised phase III trial of prophylaxis or pre-emptive CMV therapy in the ICU population, currently seem promissory. Given the significant impact and the limited current therapeutic options for critical illness, the availability of antiviral options for CMV, and the clinical observational data supporting a potential pathogenic role for CMV in the ICU population 5, 9 , there is presently a sound rationale for an initial 'proof of concept' study of CMV prophylaxis (or pre-emptive CMV therapy) in the ICU setting, to improve outcomes for critically ill patients.
What are some of the challenges for proof of concept studies in this context? Studies of CMV reactivation will require standardised quantitative methods. Since 2010, the World Health Organization has developed an international standard and certified reference materials for verifying the levels of CMV by quantitative PCR VL testing; thus future studies should present their CMV VL data as IU/ml, rather than copies/ml as reported by Osawa et al 10 . That said, commercial CMV PCR assays that measure quantitative CMV VL in IU/ml are not entirely without their own problems; for example recent studies show matrix-associated commutability issues with some results obtained from these platforms 11 . Therefore, even the current internationally agreed gold standard has limitations, pending further platform and/or assay performance improvements. CMV VL assays in whole blood (or plasma) are preferred to quantitative antigenaemia assays, as leukopenia can be secondary to CMV reactivation, sepsis or host immunosuppression. Recruitment issues arise in many studies and the relatively slow patient accrual in the study by Osawa et al 10 highlights this difficulty. Further, most ICU studies of new therapies are unlikely to have an intervention that has >3% absolute attributable increase in patient survival 1 . Hence survival alone, or overall mortality, is unlikely to be a viable primary endpoint. Therefore, another primary endpoint would be required, perhaps a composite endpoint, although the optimal choice remains ill-defined. Given protean contributors to ICU patient mortality, the use of surrogate endpoints such as length of stay or ventilator days may allow a smaller sample size in any such trial. The antiviral choice requires further consideration. Ganciclovir or valganciclovir as the best studied antivirals for CMV have significant risks of cytopenias. Newer agents such as maribavir, brincidofovir and letermovir have fewer adverse effects excepting diarrhoea with brincidofovir; letermovir and brincidofovir have demonstrated prophylactic efficacy following haematopoietic stem cell transplantation 13, 14 .
Though not used to treat CMV infection, valaciclovir has efficacy for CMV prophylaxis, and may also warrant further study.
Novel prospects in the field?
CMV-specific immune function assays (also called interferon-γ release assays [IGRAs]) such as CMV-ELISpot® and CMV-QuantiFERON® in solid and haematopoietic stem cell transplant populations have demonstrated that active CMV T cell specific immunity is associated with a lower incidence of CMV infection and disease [15] [16] [17] [18] [19] [20] . Looking forward, assessing T cell-mediated immune responses using IGRAs in parallel with CMV viral load assays are likely worthwhile investigations when studying CMV reactivation in critically ill ICU patients. CMV-IGRAs might even be useful to risk-stratify those patients in the ICU setting at the highest risk of CMV reactivation. Secondly, biomarkers with potential predictive value such as soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and the utility of other surrogate biomarkers 21 could be examined in critically ill ICU patients, including those patients with direct and/or indirect effects of CMV reactivation accompanied by sepsis. Thirdly, there is burgeoning research in the field of ICU outcomes research of 'Omics' 22, 23 , with novel technologies that facilitate highthroughput screening of sepsis biomarkers offering innovative tools to overcome our present diagnostic and prognostic limitations. Interestingly, ICU-acquired infections occur more commonly in those with sepsis and with higher disease severity at presentation, but such infections only contribute modestly (~2% at 60 days) to the absolute increase in patient mortality 24 . Intriguingly, at the start of late-onset ICU sepsis, leukocyte whole-genome transcriptome responses in those patients with sepsis were largely consistent with host immune suppression 24 . Host genetic polymorphisms, together with individual host whole-genome leukocyte expression profiles seen in response to ICU-acquired sepsis, are likely to contribute to the interplay between the pro-inflammatory and anti-inflammatory immune responses 24, 25 . The study by Osawa et al 10 , further reinforces the point that early-versus late-onset ICU sepsis populations are qualitatively quite different patient cohorts, with perhaps different immune responses and/or distinct host polymorphisms with hostspecific transcriptional sepsis response signatures (SRS) 23 . Whilst there is also ongoing progress with the development of a CMV vaccine, its utility in reducing CMV reactivation in the ICU is currently unclear.
Conclusions
Severe sepsis care is complex, requiring vigorous fluid resuscitation, early antibiotics, infective source control, vasopressors, and blood products. Sepsis outcomes are better now than a decade ago, including outside randomised trials 26 ; much of this improvement is from our earlier recognition and more aggressive early ICU care of sepsis. Herein Osawa et al 10 confirm a strong association linking BSI with CMV reactivation in the ICU setting to subsequent patient outcomes; nonetheless, causal linkages to CMV reactivation and specific patient outcomes currently remain elusive. Proof of concept antiviral trials are likely needed to advance our understanding of the clinical impact of this virus in critically ill ICU patients, arguably best facilitated by measures of CMV-specific immunity and using specific biomarkers or other more precise host-specific transcriptional SRS profiles [21] [22] [23] . Precision medicine, in which individualised therapies are provided to patients derived from their specific genomic and cellular alterations accompanying severe sepsis, could revolutionise the future treatment of critically ill ICU patients-including those with CMV viraemia.
